Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey
Authors:
Open Access
- 1 January 2023
- journal article
- research article
- Published by Medknow in Journal of Current Ophthalmology
- Vol. 35 (1) , 61-65
Abstract
Purpose: To evaluate the clinical and demographic aspects of off-label drug use applications for age-related macular degeneration (AMD) in Turkey. Methods: Applications for off-label drug use in the treatment of AMD to the Turkish Medicines and Medical Devices Agency (TITCK) in 2018 were retrospectively analyzed. Demographic characteristics, requested drugs, previous treatment regimens, and reasons for applications were evaluated. Results: The mean age of the patients (n = 209) was 64.9 ± 15.7 years, of which 48.8% were male and 51.2% were female. Ranibizumab (n = 113) comprised 54.1% and aflibercept (n = 96) 45.9% of off-label use applications. No application was made for bevacizumab. The most frequent reasons for application were switchback (49.3%), nonreimbursement of indicated drugs in cases under 50 years of age (24.4%), and failure to complete the loading dose (14.4%). Conclusions: Ranibizumab was the most requested off-label drug for AMD. There was no application for off-label bevacizumab since its use does not require approval from TITCK. In Turkey, new rules were established for the reimbursement of intravitreal drugs for AMD in 2019. Three doses of intravitreal bevacizumab were required initially for aflibercept and ranibizumab to be covered for reimbursement. There is not enough data in the English literature regarding the off-label use of ranibizumab and aflibercept for AMD. This study provides information about drug regulations and the off-label treatment options preferred by physicians for AMD in Turkey.Keywords
This publication has 23 references indexed in Scilit:
- A nationwide evaluation of off-label drug utilization in TurkeyTURKISH JOURNAL OF MEDICAL SCIENCES, 2017
- Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factorsEye and Vision, 2016
- Photodynamic therapy: current role in the treatment of chorioretinal conditionsEye, 2016
- The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic reviewBMJ Open, 2014
- Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial)Eye, 2013
- Ten Common Questions (and Their Answers) About Off-label Drug UseMayo Clinic Proceedings, 2012
- Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicinesGraefe's Archive for Clinical and Experimental Ophthalmology, 2012
- Drug, Patient, and Physician Characteristics Associated With Off-label Prescribing in Primary CareArchives of internal medicine (1960), 2012
- Regulating Off-Label Drug Use — Rethinking the Role of the FDANew England Journal of Medicine, 2008
- Off-label Drug Use in Hospitalized ChildrenArchives of Pediatrics & Adolescent Medicine, 2007